WO2007132175A3 - Inhibitors of hcap18/ll-37 for use in the treatment of breast cancer - Google Patents

Inhibitors of hcap18/ll-37 for use in the treatment of breast cancer Download PDF

Info

Publication number
WO2007132175A3
WO2007132175A3 PCT/GB2007/001653 GB2007001653W WO2007132175A3 WO 2007132175 A3 WO2007132175 A3 WO 2007132175A3 GB 2007001653 W GB2007001653 W GB 2007001653W WO 2007132175 A3 WO2007132175 A3 WO 2007132175A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcap18
agent
inhibitors
treatment
breast cancer
Prior art date
Application number
PCT/GB2007/001653
Other languages
French (fr)
Other versions
WO2007132175A2 (en
Inventor
Mona Stahle
Guenther Weber
Original Assignee
Lipopeptide Ab
Smith Stephen Edward
Mona Stahle
Guenther Weber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipopeptide Ab, Smith Stephen Edward, Mona Stahle, Guenther Weber filed Critical Lipopeptide Ab
Priority to CA002651064A priority Critical patent/CA2651064A1/en
Priority to AU2007251359A priority patent/AU2007251359A1/en
Priority to EP07732682A priority patent/EP2032699A2/en
Priority to JP2009508468A priority patent/JP2009535391A/en
Publication of WO2007132175A2 publication Critical patent/WO2007132175A2/en
Publication of WO2007132175A3 publication Critical patent/WO2007132175A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

The present invention provides agents for inhibiting the metastasis of cancer cells wherein the agent inhibits the biological activity of hCAP18/LL-37. In a preferred embodiment, the agent alters the transcription, translation and/o binding properties of hCAP18/LL-37. Preferably, the agent is selected from th group consisting of short interfering RNA (siRNA) molecules, antisens oligonucleotides and compounds with binding affmity for hCAP18/LL-37 or it receptor(s). The invention further provides methods for inhibiting the metastasis of cancer cells in a patient, as well as methods and kits for diagnosing cancer.
PCT/GB2007/001653 2006-05-04 2007-05-04 Inhibitors of hcap18/ll-37 for use in the treatment of breast cancer WO2007132175A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002651064A CA2651064A1 (en) 2006-05-04 2007-05-04 Novel agents and use thereof
AU2007251359A AU2007251359A1 (en) 2006-05-04 2007-05-04 Inhibitors of hCAP18/LL-37 for use in the treatment of breast cancer
EP07732682A EP2032699A2 (en) 2006-05-04 2007-05-04 Inhibitors of hcap18/ll-37 for use in the treatment of breast cancer
JP2009508468A JP2009535391A (en) 2006-05-04 2007-05-04 Inhibitors of hCAP18 / LL-37 for use in the treatment of breast cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0608797.7A GB0608797D0 (en) 2006-05-04 2006-05-04 Novel agents and the use thereof
GB0608797.7 2006-05-04

Publications (2)

Publication Number Publication Date
WO2007132175A2 WO2007132175A2 (en) 2007-11-22
WO2007132175A3 true WO2007132175A3 (en) 2008-05-22

Family

ID=36603894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/001653 WO2007132175A2 (en) 2006-05-04 2007-05-04 Inhibitors of hcap18/ll-37 for use in the treatment of breast cancer

Country Status (7)

Country Link
EP (1) EP2032699A2 (en)
JP (1) JP2009535391A (en)
CN (1) CN101479385A (en)
AU (1) AU2007251359A1 (en)
CA (1) CA2651064A1 (en)
GB (1) GB0608797D0 (en)
WO (1) WO2007132175A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010121208A2 (en) * 2009-04-16 2010-10-21 Forsyth Dental Infirmary For Children New methods of making an antibody and compositions thereof
CN101787368B (en) * 2009-12-17 2013-03-27 湖南师范大学 siRNA for restraining Z38 gene expression of human being and application thereof in preparing breast-tumor resisting medicine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1358888A1 (en) * 2002-02-28 2003-11-05 Robert Bals The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis
WO2004056307A2 (en) * 2002-12-19 2004-07-08 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
WO2006067402A2 (en) * 2004-12-22 2006-06-29 Lipopeptide Ab Agents inibiting the cathelin-like protein cap18/ll-37

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1358888A1 (en) * 2002-02-28 2003-11-05 Robert Bals The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis
WO2004056307A2 (en) * 2002-12-19 2004-07-08 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
WO2006067402A2 (en) * 2004-12-22 2006-06-29 Lipopeptide Ab Agents inibiting the cathelin-like protein cap18/ll-37

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEILBORN J D ET AL: "Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 114, no. 5, 1 May 2005 (2005-05-01), pages 713 - 719, XP002381680, ISSN: 0020-7136 *
WEBER G ET AL: "Vitamin D induces the antimicrobial protein hCAP18 in human skin", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NEW YORK, NY, US, vol. 124, May 2005 (2005-05-01), pages 1080 - 1082, XP002459130, ISSN: 0022-202X *

Also Published As

Publication number Publication date
CN101479385A (en) 2009-07-08
GB0608797D0 (en) 2006-06-14
JP2009535391A (en) 2009-10-01
WO2007132175A2 (en) 2007-11-22
AU2007251359A1 (en) 2007-11-22
EP2032699A2 (en) 2009-03-11
CA2651064A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
WO2005084109A3 (en) Cancer specific gene mh15
Zhang et al. LncRNA H19 is overexpressed in glioma tissue, is negatively associated with patient survival, and promotes tumor growth through its derivative miR-675.
MX2010002113A (en) Methods for detecting oligonucleotides.
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
EP1888786A4 (en) Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
WO2006012468A3 (en) Detection of oligonuleotides by dual hybridization
MX2009004510A (en) Oligoribonucleotides and uses thereof.
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
MXPA06014175A (en) Diagnosing or predicting the course of breast cancer.
NZ593229A (en) Gene expression markers (gadd45b) for colorectal cancer prognosis
WO2006132971A3 (en) Identification of tumors and tissues
BRPI0517613A (en) oligonucleotides lna and cancer treatment
WO2006067402A3 (en) Agents inibiting the cathelin-like protein cap18/ll-37
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008134596A3 (en) Use of methylated or unmethylated line-i dna as a cancer marker
MX2009008508A (en) Compositions and methods to prevent cancer with cupredoxins.
WO2008113111A8 (en) Assay for gene expression
WO2010033773A3 (en) Diagnostic, prognostic and therapeutic uses of mirs in adaptive pathways and/or disease pathways
WO2008070663A3 (en) Companion diagnostic assays for cancer therapy
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
WO2008107114A3 (en) Control genes for the normalization of gene expression analysis data
ATE414277T1 (en) METHOD FOR PREVENTING TIME-DEPENDENT RNA EXPRESSION IN BIOLOGICAL CELLS
WO2007137679A3 (en) Device and substance for isolating mesenchymal stem cells (msc)
WO2004045544A8 (en) Autocrine growth factor receptor antibodies and methods
WO2007132175A3 (en) Inhibitors of hcap18/ll-37 for use in the treatment of breast cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780023565.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007732682

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07732682

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 4350/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009508468

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2651064

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007251359

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007251359

Country of ref document: AU

Date of ref document: 20070504

Kind code of ref document: A